Total Valuation
Viridian Therapeutics has a market cap or net worth of €1.81B. The enterprise value is €1.42K.
Market Cap€1.81B
Enterprise Value€1.42K
Share Statistics
Viridian Therapeutics has 110,427,680 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding110,427,680
Owned by Insiders4.66%
Owned by Institutions3.37%
Financial Efficiency
Viridian Therapeutics’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -43.81%.
Return on Equity (ROE)-0.47
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-43.81%
Return on Capital Employed (ROCE)-0.44
Revenue Per Employee281.15K
Profits Per Employee-1.36M
Employee Count252
Asset Turnover0.08
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Viridian Therapeutics is ―. Viridian Therapeutics’s PEG ratio is 0.57.
PE Ratio―
PS Ratio37.25
PB Ratio3.65
Price to Fair Value3.65
Price to FCF-9.53
Price to Operating Cash Flow-7.10
PEG Ratio0.57
Income Statement
In the last 12 months, Viridian Therapeutics had revenue of 70.85M and earned -342.60M in profits. Earnings per share was -3.32.
Revenue70.85M
Gross Profit70.85M
Operating Income-363.39M
Pretax Income-342.60M
Net Income-342.60M
EBITDA-337.19M
Earnings Per Share (EPS)-3.32
Cash Flow
In the last 12 months, operating cash flow was -333.34M and capital expenditures -1.70M, giving a free cash flow of -335.04M billion.
Operating Cash Flow-333.34M
Free Cash Flow-335.04M
Free Cash Flow per Share-3.03
Dividends & Yields
Viridian Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.17
52-Week Price Change20.81%
50-Day Moving Average15.77
200-Day Moving Average20.45
Relative Strength Index (RSI)62.20
Average Volume (3m)107.00
Important Dates
Viridian Therapeutics upcoming earnings date is Nov 16, 2026, TBA (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateNov 16, 2026
Ex-Dividend Date―
Financial Position
Viridian Therapeutics as a current ratio of 12.65, with Debt / Equity ratio of 8.05%
Current Ratio12.65
Quick Ratio12.65
Debt to Market Cap0.02
Net Debt to EBITDA0.48
Interest Coverage Ratio-73.44
Taxes
In the past 12 months, Viridian Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Viridian Therapeutics EV to EBITDA ratio is -7.35, with an EV/FCF ratio of -8.95.
EV to Sales34.97
EV to EBITDA-7.35
EV to Free Cash Flow-8.95
EV to Operating Cash Flow-8.96
Balance Sheet
Viridian Therapeutics has €981.53M in cash and marketable securities with €242.16M in debt, giving a net cash position of €739.37M billion.
Cash & Marketable Securities€981.53M
Total Debt€242.16M
Net Cash€739.37M
Net Cash Per Share€6.70
Tangible Book Value Per Share€8.52
Margins
Gross margin is 99.38%, with operating margin of -512.91%, and net profit margin of -483.57%.
Gross Margin99.38%
Operating Margin-512.91%
Pretax Margin-483.57%
Net Profit Margin-483.57%
EBITDA Margin-475.93%
EBIT Margin-476.58%
Analyst Forecast
The average price target for Viridian Therapeutics is €29.18, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€29.18
Price Target Upside73.71% Upside
Analyst ConsensusStrong Buy
Analyst Count12
Revenue Growth Forecast21491.30%
EPS Growth Forecast13.58%